MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1038/s41571-026-01190-7

Медицинская библиотека · Nature reviews. Clinical oncology · 2026

Exploring the landscape of targetable alterations in patients with glioblastoma.

Aquilanti Elisa, Touat Mehdi, French Pim, Iavarone Antonio, Capper David, Geurts Marjolein, Rahman Rifaquat, Verhaak Roel, Preusser Matthias, van den Bent Martin, Wen Patrick Y

СтатьяОбзорПеревод в очереди

Аннотация

Glioblastomas remain the most lethal primary brain tumour in adults, with targeted therapies delivering only limited benefit despite deep molecular characterization. Several targeted drugs have received regulatory approval for low-grade gliomas, although progress in glioblastomas remains constrained by, among other aspects, extensive intratumoural heterogeneity, pathway redundancy, cellular plasticity and limited drug delivery to the central nervous system. Some of these challenges might be mitigated through strategies that enhance blood-brain penetration, including focused ultrasonography, convection-enhanced delivery, efflux avoidance and chemical modifications. Improved tumour profiling through multiregional sampling, prioritization of truncal dependencies and the development of novel therapeutic modalities, such as antibody-drug conjugates and theranostics, might also further improve outcomes. In this Review, we summarize the therapeutic landscape of targeted therapies in glioblastomas, spanning major target classes including receptor tyrosine kinases, intracellular signalling proteins, cell-cycle dysregulation and synthetic-lethal vulnerabilities. We also examine emerging strategies targeting genome integrity and telomeres, epigenetic modulators, and tumour-neural circuitry. Furthermore, we highlight tumour heterogeneity and extrachromosomal DNA dynamics as key drivers of oncogene amplification and therapeutic resistance as well as the roles of novel clinical trial designs and liquid biopsy-based monitoring strategies. Lastly, we discuss pathway-based glioblastoma classification and master kinase mapping as methods for aligning drugs with functional tumour states.

Для цитирования: Aquilanti Elisa, Touat Mehdi, French Pim, Iavarone Antonio, Capper David, Geurts Marjolein, Rahman Rifaquat, Verhaak Roel, Preusser Matthias, van den Bent Martin, Wen Patrick Y. Exploring the landscape of targetable alterations in patients with glioblastoma.. Nature reviews. Clinical oncology. 2026. DOI: 10.1038/s41571-026-01190-7.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.